--- title: Eric Shrayer Discusses the Next Wave of Weight-Loss Therapies with Investor’s Business Daily description: Explore insights from Eric Shrayer on the future of GLP-1 obesity therapies, regulatory challenges, and the market dynamics surrounding Eli Lilly’s retatrutide. image: https://blog.reyndersmcveigh.com/hubfs/RM_E%20Shrayer%20IBD_media%20hit%20graphic_05.08.26.jpg --- [![horizontal](https://blog.reyndersmcveigh.com/hubfs/horizontal.svg "horizontal")](https://reyndersmcveigh.com/) - [About](https://reyndersmcveigh.com/about) - [Who we are](https://reyndersmcveigh.com/who) - [Our Team](https://reyndersmcveigh.com/team) - [Contact](https://reyndersmcveigh.com/contact) - [Careers](https://reyndersmcveigh.com/careers) - [Services](https://reyndersmcveigh.com/services) - [Investment Management](https://reyndersmcveigh.com/investment-management) - [Financial Planning](https://reyndersmcveigh.com/financial-planning) - [Sustainable Investing](https://reyndersmcveigh.com/sustainable-investing) - [Insights](https://blog.reyndersmcveigh.com/insights) - [Forms](https://reyndersmcveigh.com/compliance) - [Form CRS](https://reyndersmcveigh.com/crs) - [Form ADV](https://reyndersmcveigh.com/s/2024-06-18-ADV-Part-2A.pdf) - [Mutual Fund](http://www.reyndersmcveighfunds.com/) [Log In](https://reyndersmcveigh.sharefile.com/Authentication/Login) [Log In](https://reyndersmcveigh.sharefile.com/Authentication/Login) May 26 # Eric Shrayer Discusses the Next Wave of Weight-Loss Therapies with Investor’s Business Daily ![RM_E Shrayer IBD_media hit graphic_05.08.26](https://blog.reyndersmcveigh.com/hs-fs/hubfs/RM_E%20Shrayer%20IBD_media%20hit%20graphic_05.08.26.jpg?width=1243&height=699&name=RM_E%20Shrayer%20IBD_media%20hit%20graphic_05.08.26.jpg) Few categories in healthcare have generated as much investor enthusiasm as GLP-1 obesity therapies. For long-term investors, one of the challenges is separating the size of the addressable market from the operational and regulatory realities that will determine which franchises actually compound value over time. That tension framed recent commentary from Eric Shrayer, Partner and Director of Research at Reynders, McVeigh Capital Management, in a conversation with Investor’s Business Daily about Eli Lilly’s investigational triple-agonist retatrutide. While Phase 3 data and analyst forecasts point to a potential blockbuster, an unregulated black-market supply chain has already emerged around the drug — well before the FDA has had a chance to review it.   Shrayer pointed to the limits of what regulators can do while a therapy is still in clinical testing.   **“It’s like a game of whack-a-mole,” Shrayer told IBD.**   Until retatrutide receives FDA approval, enforcement against unauthorized compounders sits largely with the agency’s warning letters and referrals to state attorneys general. Once approval is in hand, Shrayer expects Lilly to be **“**very aggressive**”** in protecting the franchise.   He also flagged a longer-horizon question that often gets lost in the demand story: the population-level impact of broad GLP-1 use over time.   **“We haven’t really seen the impact of what this would have on a population over a long time frame, on a population that doesn’t necessarily need it,” Shrayer said. “I think we’ll learn as we go.”**   For Reynders, McVeigh, evaluating opportunities in this category means looking past peak-sales projections to weigh durability and risks in the context of the therapeutic shift. We believe that while blockbusters can bring benefit, the real discipline lies in understanding the nuances of each company we own, rather than potential profits from a big “hit.”   Access the full article here (subscription): [Eli Lilly’s Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Off](https://www.investors.com/news/technology/eli-lilly-weight-loss-drug-retatrutide-black-market/)     DISCLOSURES:   *Reynders, McVeigh Capital Management, LLC ("RMCM") is a registered investment adviser. Registration with the U.S. Securities and Exchange Commission does not imply a certain level of skill or training.*   *The commentary provided is for informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Any companies or investments referenced are presented solely as illustrative examples of the themes discussed and do not represent all securities purchased, sold, or recommended for advisory clients. It should not be assumed that any investment in such companies has been or will be profitable. A complete list of RMCM's recommendations over the past 12 months is available upon request.*   *By clicking the link above, you are leaving the RMCM website and entering a third-party site. RMCM is not responsible for the accuracy or content of information contained on third-party sites.*       - ## [Shareholder Engagement Proxy Newsletter 2025](https://blog.reyndersmcveigh.com/insights/shareholder-engagement-proxy-newsletter-2025) - ## [Carrie Endries Joins ImpactAlpha’s Agents of Impact to Discuss Private Impact Investing](https://blog.reyndersmcveigh.com/insights/carrie-endries-joins-impactalphas-agents-of-impact-to-discuss-private-impact-investing) © Reynders, McVeigh Capital Management 10 Post Office Square, Suite N1010 Boston, MA 02109 Phone: 617.226.9999 Fax: 617.226.9998 - [About](https://reyndersmcveigh.com/about) - [Services](https://reyndersmcveigh.com/services) - [Sustainable Investing](https://reyndersmcveigh.com/sustainable-investing) - [Insights](https://reyndersmcveigh.com/insights) - [Mutual Fund](http://www.reyndersmcveighfunds.com/) - [Form CRS](https://reyndersmcveigh.com/crs) - [Form ADV](https://reyndersmcveigh.com/s/2026-03-31-Form-ADV-Part-2A.pdf) Important disclosures. Views expressed within Insights are those of the authors as of the time of publication; such views are subject to change at any time based on market or other conditions. These views are not intended to be a forecast of future events or a guarantee of future results and may not be relied upon as investment advice. The information contained herein has been prepared from sources believed reliable but is not guaranteed by us as to its timeliness or accuracy, and is not a complete summary or statement of all available data. This is not a recommendation to buy or sell the securities mentioned. Any securities mentioned were selected on an objective basis for illustrative purposes and do not represent all of the securities purchased, sold or recommended. It should not be assumed that investments in any securities mentioned has been or will be profitable. The securities do not represent all of the securities purchased, sold or recommended for advisory clients.Past performance is no guarantee of future results. Every investment carries the potential for both profit and loss. Past performance is no guarantee of future results. Every investment carries the potential for both profit and loss. By clicking on hyperlinks, you are leaving the Reynders, McVeigh website and entering a third-party site. Reynders, McVeigh is not responsible for information contained on the third-party sites. ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Reynders, McVeigh Capital Management", "url" : "https://blog.reyndersmcveigh.com/insights/author/reynders-mcveigh-capital-management" }, "dateModified" : "2026-05-26T15:24:16.428Z", "datePublished" : "2026-05-26T15:24:16.000Z", "headline" : "Eric Shrayer Discusses the Next Wave of Weight-Loss Therapies with Investor’s Business Daily", "image" : [ "https://blog.reyndersmcveigh.com/hubfs/RM_E%20Shrayer%20IBD_media%20hit%20graphic_05.08.26.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.reyndersmcveigh.com/insights/eric-shrayer-discusses-the-next-wave-of-weight-loss-therapies-with-investors-business-daily", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.reyndersmcveigh.com/hubfs/horizontal-1.svg" } } } ```